212 related articles for article (PubMed ID: 24327582)
1. A disintegrin and metalloproteinases 10 and 17 modulate the immunogenicity of glioblastoma-initiating cells.
Wolpert F; Tritschler I; Steinle A; Weller M; Eisele G
Neuro Oncol; 2014 Mar; 16(3):382-91. PubMed ID: 24327582
[TBL] [Abstract][Full Text] [Related]
2. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17.
Chitadze G; Lettau M; Bhat J; Wesch D; Steinle A; Fürst D; Mytilineos J; Kalthoff H; Janssen O; Oberg HH; Kabelitz D
Int J Cancer; 2013 Oct; 133(7):1557-66. PubMed ID: 23526433
[TBL] [Abstract][Full Text] [Related]
3. Effects of ADAM10 and ADAM17 Inhibitors on Natural Killer Cell Expansion and Antibody-dependent Cellular Cytotoxicity Against Breast Cancer Cells
Pham DH; Kim JS; Kim SK; Shin DJ; Uong NT; Hyun H; Yoon MS; Kang SJ; Ryu YJ; Cho JS; Yoon JH; Lee JS; Cho D; Lee SH; Park MH
Anticancer Res; 2017 Oct; 37(10):5507-5513. PubMed ID: 28982863
[TBL] [Abstract][Full Text] [Related]
4. The good, the bad and the ugly substrates for ADAM10 and ADAM17 in brain pathology, inflammation and cancer.
Pruessmeyer J; Ludwig A
Semin Cell Dev Biol; 2009 Apr; 20(2):164-74. PubMed ID: 18951988
[TBL] [Abstract][Full Text] [Related]
5. Improved synthesis of ADAM10 inhibitor GI254023X.
Hoettecke N; Ludwig A; Foro S; Schmidt B
Neurodegener Dis; 2010; 7(4):232-8. PubMed ID: 20197648
[TBL] [Abstract][Full Text] [Related]
6. The ADAM10 prodomain is a specific inhibitor of ADAM10 proteolytic activity and inhibits cellular shedding events.
Moss ML; Bomar M; Liu Q; Sage H; Dempsey P; Lenhart PM; Gillispie PA; Stoeck A; Wildeboer D; Bartsch JW; Palmisano R; Zhou P
J Biol Chem; 2007 Dec; 282(49):35712-21. PubMed ID: 17895248
[TBL] [Abstract][Full Text] [Related]
7. The isolated N-terminal domains of TIMP-1 and TIMP-3 are insufficient for ADAM10 inhibition.
Rapti M; Atkinson SJ; Lee MH; Trim A; Moss M; Murphy G
Biochem J; 2008 Apr; 411(2):433-9. PubMed ID: 18215140
[TBL] [Abstract][Full Text] [Related]
8. The "A Disintegrin And Metalloproteases" ADAM10 and ADAM17: novel drug targets with therapeutic potential?
Saftig P; Reiss K
Eur J Cell Biol; 2011; 90(6-7):527-35. PubMed ID: 21194787
[TBL] [Abstract][Full Text] [Related]
9. Anticancer chemotherapy inhibits MHC class I-related chain a ectodomain shedding by downregulating ADAM10 expression in hepatocellular carcinoma.
Kohga K; Takehara T; Tatsumi T; Miyagi T; Ishida H; Ohkawa K; Kanto T; Hiramatsu N; Hayashi N
Cancer Res; 2009 Oct; 69(20):8050-7. PubMed ID: 19826051
[TBL] [Abstract][Full Text] [Related]
10. Soluble Axl is generated by ADAM10-dependent cleavage and associates with Gas6 in mouse serum.
Budagian V; Bulanova E; Orinska Z; Duitman E; Brandt K; Ludwig A; Hartmann D; Lemke G; Saftig P; Bulfone-Paus S
Mol Cell Biol; 2005 Nov; 25(21):9324-39. PubMed ID: 16227584
[TBL] [Abstract][Full Text] [Related]
11. Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30.
Schlecker E; Fiegler N; Arnold A; Altevogt P; Rose-John S; Moldenhauer G; Sucker A; Paschen A; von Strandmann EP; Textor S; Cerwenka A
Cancer Res; 2014 Jul; 74(13):3429-40. PubMed ID: 24780758
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a new selective inhibitor of A Disintegrin And Metalloprotease 10 (ADAM-10) able to reduce the shedding of NKG2D ligands in Hodgkin's lymphoma cell models.
Camodeca C; Nuti E; Tepshi L; Boero S; Tuccinardi T; Stura EA; Poggi A; Zocchi MR; Rossello A
Eur J Med Chem; 2016 Mar; 111():193-201. PubMed ID: 26871660
[TBL] [Abstract][Full Text] [Related]
13. Metalloproteinase inhibitors for the disintegrin-like metalloproteinases ADAM10 and ADAM17 that differentially block constitutive and phorbol ester-inducible shedding of cell surface molecules.
Ludwig A; Hundhausen C; Lambert MH; Broadway N; Andrews RC; Bickett DM; Leesnitzer MA; Becherer JD
Comb Chem High Throughput Screen; 2005 Mar; 8(2):161-71. PubMed ID: 15777180
[TBL] [Abstract][Full Text] [Related]
14. High ERp5/ADAM10 expression in lymph node microenvironment and impaired NKG2D ligands recognition in Hodgkin lymphomas.
Zocchi MR; Catellani S; Canevali P; Tavella S; Garuti A; Villaggio B; Zunino A; Gobbi M; Fraternali-Orcioni G; Kunkl A; Ravetti JL; Boero S; Musso A; Poggi A
Blood; 2012 Feb; 119(6):1479-89. PubMed ID: 22167753
[TBL] [Abstract][Full Text] [Related]
15. Differential surface expression of ADAM10 and ADAM17 on human T lymphocytes and tumor cells.
Ebsen H; Schröder A; Kabelitz D; Janssen O
PLoS One; 2013; 8(10):e76853. PubMed ID: 24130797
[TBL] [Abstract][Full Text] [Related]
16. Selective use of ADAM10 and ADAM17 in activation of Notch1 signaling.
Bozkulak EC; Weinmaster G
Mol Cell Biol; 2009 Nov; 29(21):5679-95. PubMed ID: 19704010
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel inhibitors of a disintegrin and metalloprotease 17 (ADAM17) using glycosylated and non-glycosylated substrates.
Minond D; Cudic M; Bionda N; Giulianotti M; Maida L; Houghten RA; Fields GB
J Biol Chem; 2012 Oct; 287(43):36473-87. PubMed ID: 22927435
[TBL] [Abstract][Full Text] [Related]
18. Induction of RAGE shedding by activation of G protein-coupled receptors.
Metz VV; Kojro E; Rat D; Postina R
PLoS One; 2012; 7(7):e41823. PubMed ID: 22860017
[TBL] [Abstract][Full Text] [Related]
19. Fluorescent substrates for the proteinases ADAM17, ADAM10, ADAM8, and ADAM12 useful for high-throughput inhibitor screening.
Moss ML; Rasmussen FH
Anal Biochem; 2007 Jul; 366(2):144-8. PubMed ID: 17548045
[TBL] [Abstract][Full Text] [Related]
20. N-terminal cleavage and release of the ectodomain of Flt1 is mediated via ADAM10 and ADAM 17 and regulated by VEGFR2 and the Flt1 intracellular domain.
Raikwar NS; Liu KZ; Thomas CP
PLoS One; 2014; 9(11):e112794. PubMed ID: 25387128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
